The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.
Aditya Bardia
Research Funding - Novartis
Shanu Modi
Research Funding - Novartis
Mariana Chavez-Mac Gregor
Research Funding - Novartis
Expert Testimony - Novartis
Muaiad Kittaneh
Research Funding - Novartis
Alyssa J. Marino
Employment or Leadership Position - Novartis Institutes of Biomedical Research
Alessandro Matano
Employment or Leadership Position - Novartis
Suraj Bhansali
Employment or Leadership Position - Novartis
Becker Hewes
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Javier Cortes
Consultant or Advisory Role - Celgene; Novartis; Roche
Honoraria - Celgene; Eisai; Novartis; Roche